Drug Diversion Monitoring in Hospitals: The Complete Guide

What Is Drug Diversion Monitoring?

Drug diversion monitoring is the practice of tracking controlled substance transactions across a health system to detect when medications are stolen, misused, or redirected by healthcare workers. Drug diversion covers the full medication journey, from purchase and receipt at the wholesaler, through dispensing at the automated dispensing cabinet (ADC), to administration at the bedside, waste, and return.

The term “drug diversion” refers to any unauthorized removal or use of a prescription medication outside its intended patient care purpose. A nurse who pockets fentanyl from a patient’s infusion. A pharmacy technician who skims doses from a controlled substance vault. An anesthesia provider who substitutes saline for a narcotic and pockets the difference. All of these are drug diversion, and all of them go undetected more often than health system leaders expect.

According to the 2026 State of Hospital Pharmacy Operations Report (HPOR) from Bluesight, nearly 63% of healthcare leaders reported at least one diversion even in the last year. The International Health Facility Diversion Association estimates that at least 37,000 drug diversion incidents occur in U.S. hospitals each year. That is not a rare event – it is a predictable, ongoing risk that requires a deliberate, technology-supported program to manage.

Bluesight’s ControlCheck, the five-time Best-in-KLAS drug diversion monitoring solution, is used by more than 2,000 hospitals across the United States and Canada. The platform detects drug diversion 6.6 times more effectively than other solutions by combining automated closed-loop reconciliation, behavior-based risk scoring, and an AI assistant built specifically for controlled substance data.

Why Drug Diversion Happens in Hospitals

Drug diversion happens because healthcare settings provide consistent, largely unsupervised access to high-value controlled substances. Opioids, benzodiazepines, stimulants, and anesthetic agents are present in large volumes throughout hospitals, and the workflows required to administer them create dozens of opportunities for small discrepancies to go unnoticed.

Contributing factors include:

• Substance use disorder among healthcare workers. The American Nurses Association and the Substance Abuse and Mental Health Services Administration estimate that approximately 10% of healthcare workers have a substance use disorder. The stress of healthcare work, ready access to potent medications, and the stigma around seeking help create conditions where diversion and self-medication are ongoing risks.
• Volume and complexity. A busy hospital dispenses thousands of controlled substance doses every day. Each dispense, administration, waste event, and return generates a transaction that must be reconciled against patient records. Without technology to automate that reconciliation, manual reviews can only sample a small fraction of activity.
• Workflow blind spots. Many diversion monitoring programs focus on nursing ADC activity but miss the operating room, procedural areas, retail pharmacy, and inpatient pharmacy itself. These blind spots are where some of the most damaging diversion events occur and go undetected for the longest periods.
• Social dynamics. Colleagues are reluctant to report suspected diversion, fearing they are wrong, that the person will lose their job, or that they will face retaliation. This hesitation means that even when behavioral warning signs are present, formal reporting often does not happen until the evidence is overwhelming.

The Scale of the Problem: Drug Diversion Statistics

Before discussing how to detect and prevent drug diversion, it is worth grounding the conversation in data.

• 81% of healthcare leaders believe drug diversion occurs frequently at their organization (2025 State of Drug Diversion Survey).
• 37,000+ drug diversion incidents are estimated to occur in U.S. healthcare facilities each year (International Health Facility Diversion Association).
• 1 in 100 healthcare workers actively diverts drugs at any given time.
• 10% of healthcare workers have a substance use disorder (American Nurses Association / SAMHSA).
• Only 37.5% of hospitals currently use AI tools for drug diversion detection, despite 76% expressing a desire for increased adoption.
• Only one-third of hospital leaders are “very confident” in their diversion program’s effectiveness (2025 State of Drug Diversion Survey).

The gap between how often diversion is believed to occur and how often it is detected is the defining challenge for any drug diversion program. Most diversion goes unseen not because the behavior is invisible, but because the monitoring infrastructure is insufficient to surface it.

How Drug Diversion Happens: Common Methods

Understanding how diversion occurs is the first step toward detecting it. Healthcare workers who divert controlled substances use a range of methods, many of which exploit predictable gaps in workflow.

• Waste diversion. A nurse documents that a partial dose was wasted but keeps the medication instead. Waste diversion is one of the most common methods because waste documentation is often inconsistently monitored and sometimes lacks a true independent witness.
• Patient diversion. Medications are dispensed for a patient but never administered. The nurse administers saline, water, or nothing and keeps the controlled substance. This method places patients at direct risk since they do not receive the pain relief they were prescribed.
• Override abuse. ADCs allow clinical staff to override normal medication dispensing procedures in urgent situations. Frequent or patterned overrides – especially for controlled substances unrelated to a nurse’s current patient assignment – are a diversion risk signal.
• Phantom patients. Medications are dispensed for patients who have been transferred, discharged, or who never had the medication ordered.
• ADC stocking diversion. Pharmacy technicians who stock ADCs have access to large quantities of controlled substances with limited oversight. Diversion can occur during the stocking process, where small amounts removed from each pocket are difficult to detect without reconciliation.
• Anesthesia diversion. Anesthesia providers have open access to high-potency opioids, often in a fast-paced procedural environment where documentation is not always contemporaneous with administration. Diversion in the OR is notoriously difficult to detect because anesthesia workflows differ from standard nursing workflows.
• Infusion manipulation. For patients receiving continuous infusions, a diverter can reduce the concentration or flow rate while documenting full administration, or substitute a bag with diluted or alternate contents.
• Retail and outpatient pharmacy diversion. Hospital-owned retail pharmacies face a distinct set of vulnerabilities. Diversion can occur at the point of dispensing, during inventory management, or through prescription manipulation. These settings are often excluded from diversion monitoring programs entirely, creating an addressable blind spot.

What Is a Drug Diversion Prevention Program?

A drug diversion prevention program is the combination of policies, workflows, staffing, technology, and culture that a health system uses to detect, investigate, and respond to controlled substance diversion.

The American Society of Health-System Pharmacists (ASHP) published updated guidelines on preventing diversion of controlled substances in 2022, providing a comprehensive framework for hospitals. The Joint Commission also addresses diversion as a patient safety priority, and the DEA requires hospitals to maintain accurate records, report theft and significant loss, and cooperate with inspections.

A comprehensive drug diversion prevention program includes the following components.

Governance and Oversight

An effective program requires a formal governance structure. Most successful programs appoint a dedicated drug diversion compliance officer or a multidisciplinary governance committee that includes pharmacy, nursing, anesthesia, security, risk management, legal, HR, and compliance. Executive-level buy-in matters: research has found that more than half of program budgets are owned by executive boards, and programs with strong C-suite engagement detect more diversion than those managed solely within the pharmacy department.

Policies and Procedures

Written policies must cover every step of the medication-use process: procurement, receipt, storage, preparation, dispensing, administration, waste, return, and removal. Policies should define access controls for all care settings, requirements for witnessed waste, processes for investigating discrepancies, and clear reporting chains for suspected diversion.

Technology and Surveillance

Manual monitoring is insufficient at scale. Technology platforms that aggregate data from ADCs, electronic health records (EHRs), wholesaler systems, HR systems, and controlled substance vaults allow diversion programs to monitor all transactions systematically – not just a sample. Automated reconciliation, behavioral analytics, and role-based risk scoring are now the standard of care for high-performing programs.

Staffing and FTE Allocation

Diversion program staffing has grown significantly. Bluesight’s HPOR found that most teams spend 5+ hours per week identifying and resolving controlled substance discrepancies. Smaller hospitals continue to struggle with minimal dedicated staffing, which increases reliance on technology to stretch limited human capacity.

Culture and Education

A culture of accountability – built on transparency, psychological safety, and clear reporting pathways – is as important as the technical infrastructure. All staff members who handle controlled substances should receive initial and annual education on diversion prevention, warning signs, and how to report concerns.

How Technology Supports Drug Diversion Monitoring

Modern drug diversion monitoring technology does what manual review cannot: it processes every single transaction, identifies statistical outliers, compares individuals to their peers, and surfaces patterns that are invisible to humans reviewing daily reports.

Automated Dispensing Cabinet Integration

ADCs are the primary data source for most diversion monitoring programs. Every medication dispense, waste event, override, and access log is captured and fed into the monitoring platform. The platform reconciles each dispense against patient administration records from the EHR, flagging discrepancies for review. ControlCheck automatically reconciles 95% of transactions, leaving diversion coordinators to focus on the 5% that require human review.

Electronic Health Record Integration

EHR integration allows the monitoring platform to cross-reference dispense data against actual patient orders, administration records, and clinical context. A nurse removing morphine from an ADC for a patient who has no active order is a flag. A dispense amount that does not match the documented administration is a flag. Without EHR integration, these discrepancies are invisible.

Wholesaler and Vault Data

Complete monitoring requires tracking medications from the point of purchase. Wholesaler data captures procurement patterns. Controlled substance vault data tracks what leaves central pharmacy and when. Reconciling these sources against what ultimately reaches patients identifies diversion that occurs upstream of the nursing floor.

Behavioral Analytics and Risk Scoring

Beyond transaction-level reconciliation, leading diversion monitoring platforms build behavioral profiles for each staff member and compare individuals to their peer group. A nurse whose waste rates are statistically higher than comparable nurses on similar units, or whose dispenses occur disproportionately at the end of a shift, presents a different risk profile than a nurse with normal patterns.

ControlCheck’s Individual Risk Identification Score (IRIS) monitors staff behavior across multiple dimensions – waste patterns, dispense timing, shift analysis, peer benchmarking, and more – and generates a risk score that prioritizes where diversion coordinators should focus their attention. This approach eliminates the reactive, complaint-driven investigation model and replaces it with proactive, data-driven surveillance.

AI and Machine Learning

Artificial intelligence is reshaping what drug diversion monitoring can detect. Machine learning models trained on historical diversion cases can identify behavioral patterns that precede a confirmed diversion event, flagging risk before significant harm has occurred. AI also reduces false positive rates over time: as the model learns from coordinator feedback on resolved and confirmed alerts, it becomes more precise about what constitutes a genuine risk signal versus a benign workflow variation.

ControlCheck’s Prism Assistant is the industry’s only AI assistant built specifically for controlled substance data. It understands the context behind your data (variances, IRIS analytics, case history) and responds to plain-language questions with structured, evidence-backed answers in under 60 seconds. Teams using Prism Assistant have reduced analysis and reporting time by up to 97%.

Drug Diversion Monitoring by Care Setting

Effective programs do not monitor only the nursing floor. Each care setting has distinct workflows, distinct vulnerabilities, and distinct monitoring requirements.

Nursing Diversion Monitoring

Nursing staff have the broadest access to controlled substances in a hospital. Monitoring focuses on ADC transaction patterns: dispense frequency, override rates, waste documentation, timing patterns relative to shift start and end, and alignment between what was dispensed and what was administered according to patient records. Alerts should be role-calibrated: a pattern that is abnormal for a medical-surgical nurse may be entirely normal for an ICU nurse.

ControlCheck is designed to be the most nurse-friendly diversion monitoring platform in the industry. Unlimited user seats allow nursing leaders and managers to participate directly in monitoring rather than waiting for pharmacy to surface concerns. This distributed visibility accelerates detection and supports the multidisciplinary collaboration that ASHP guidelines recommend.

Operating Room and Anesthesia Monitoring

The OR is one of the most challenging environments for diversion monitoring. Anesthesia providers have direct, often unsupervised access to Schedule II opioids in quantities that exceed any other clinical role. Documentation is often paper-based or completed retrospectively. The pace of procedural care makes real-time reconciliation difficult.

Monitoring in procedural settings requires matching controlled substance use against anesthesia records, procedure type, patient weight, and the expected pharmacological requirements for that case. Unusually low medication usage for a patient who should have required significant analgesia is a signal. Patterns of residual medication consistently disappearing rather than being wasted are a signal. ControlCheck’s procedural module monitors OR and anesthesia activity alongside nursing and pharmacy, eliminating the blind spot that standard programs leave open.

Inpatient Pharmacy Monitoring

Pharmacists and pharmacy technicians are responsible for the custody chain of controlled substances before they ever reach a nurse or provider. Vault overages, stocking discrepancies, frequent re-inventory of specific ADC pockets, and anomalies in return and reverse-distribution records all warrant monitoring. Because pharmacy staff have elevated access and detailed knowledge of tracking systems, diversion in pharmacy can be sophisticated and sustained.

Retail Pharmacy Monitoring

Hospital-owned retail pharmacies face a distinct and often underappreciated set of diversion risks. Unlike inpatient settings, retail pharmacy transactions involve prescriptions from external providers, walk-in patients, and dispensing workflows that differ significantly from floor-based ADC activity. Manual overrides, prescription manipulation, discrepancies between inventory received and inventory dispensed, and patterns of repeated prescriptions for specific controlled substances are all retail-specific signals.

ControlCheck’s Retail module brings the same automated reconciliation and behavioral monitoring capabilities of the inpatient platform to hospital-owned retail pharmacies. This closes a gap that most diversion programs leave completely unaddressed — an important protection for both patients and the health system’s DEA compliance posture.

What Medications Are Most Commonly Diverted?

Controlled substances are the primary target of diversion because of their high street value, addictive potential, and strict regulatory status. The most commonly diverted medications include:

• Opioids. Fentanyl, hydromorphone, oxycodone, and morphine are the most frequently diverted controlled substances. Bluesight research found that fentanyl accounts for more than 20% of drug variances. Their potency, value, and prevalence in virtually every care setting make them the defining diversion risk for hospital programs.
• Benzodiazepines. Midazolam, lorazepam, and diazepam are commonly diverted for personal use or sale. They appear across inpatient, procedural, and emergency settings.
• Stimulants. Amphetamines and methylphenidate are diverted less frequently in hospital settings but represent a risk in specific contexts.
• Anesthetic agents. Propofol, ketamine, and nitrous oxide are diverted, particularly in procedural settings.
• Non-controlled substances. An expanding risk category includes high-value non-controlled medications that are not subject to DEA scheduling but carry diversion risk due to abuse potential, street value, or performance-enhancing properties. Ondansetron (used to manage withdrawal symptoms), insulin, gabapentin, quetiapine, antivirals, and Ozempic have all appeared in confirmed diversion cases. The Joint Commission specifically cites gabapentin and quetiapine as non-controlled diversion risks. Programs that monitor only DEA-scheduled medications are leaving a growing category of risk unaddressed.

Warning Signs of Drug Diversion

Recognizing behavioral and operational warning signs of diversion is a core competency for any staff member who supervises others in a clinical setting.

Behavioral Warning Signs

• Volunteering frequently for medication-related tasks, especially at the end of a shift
• Frequent requests to administer or waste controlled substances outside their patient assignment
• Behavioral changes consistent with substance use: mood swings, impaired coordination, excessive fatigue or unusual energy, social withdrawal
• Defensiveness when questioned about documentation discrepancies
• Frequent mistakes in controlled substance counts that the employee is the first to “correct”
• Spending unusual amounts of time alone in medication rooms or near ADCs

Documentation Warning Signs

• Higher-than-average waste rates for their unit and role
• Dispenses for recently transferred or discharged patients
• Administrations without corresponding physician orders
• Waste documentation that lacks a witness, or witnesses who always sign for the same individual
• Discrepancies that are consistently resolved by the same person
• Pattern of overrides, especially for patients not on their assignment

Operational Warning Signs

• Unexplained inventory shortages in specific ADC pockets
• Patients who are in pain despite documentation showing full medication administration
• HAI clusters or bloodstream infection spikes that do not have another explanation (a pattern documented in at least one major diversion case that caused patient deaths)

How to Investigate Drug Diversion

When monitoring data flags a potential diversion, a structured investigation process is essential. ASHP guidelines, DEA regulations, and institutional risk management requirements all shape how investigations should be conducted.

Step 1: Secure and Preserve Data

Before approaching the individual or making any internal notifications beyond the immediate investigation team, secure all relevant transaction data, ADC logs, patient records, and waste documentation. Alert fatigue and premature disclosure can cause evidence to be altered or lost.

Step 2: Conduct a Thorough Data Review

Pull a complete controlled substance transaction history for the individual – typically 30 to 90 days depending on the volume of transactions and the scope of suspected activity. Review each dispense against corresponding patient records. Document every discrepancy. Map the timeline. Look for patterns across care settings, shifts, and medication types.

Step 3: Involve the Right Stakeholders

Drug diversion investigations are not a pharmacy matter alone. Nursing leadership, risk management, HR, legal counsel, and in many cases, the compliance officer must be involved. The multidisciplinary team ensures that the investigation is thorough, that the employee’s rights are protected, and that the organization’s legal and regulatory obligations are met.

Step 4: Conduct the Investigation Interview

Investigation interviews are high-stakes and must be conducted by trained personnel. The goal is to understand the facts, not to obtain a confession. The tone should be professional, non-accusatory, and methodical. Document the interview precisely.

Step 5: Report to Regulatory Authorities

Confirmed theft or significant loss of controlled substances must be reported to the DEA on Form 106 within one business day of confirmation (21 CFR 1301.76). Many hospitals fail to make this required report. Failure to do so violates DEA regulations and the Medicare Conditions of Participation. State Boards of Pharmacy and Nursing typically also require reporting.

Step 6: Address Patient Risk

Any patients who may have been harmed by the diversion (through receiving diluted or substituted medication, or through infection risk from needle reuse) must be identified and notified. This is a patient safety obligation and in many states a legal requirement.

Step 7: Close the Loop and Improve the Program

Every confirmed diversion event is a data point for program improvement. Document what the detection mechanism was, how long diversion had been occurring before detection, and what changes to monitoring, policies, or access controls would have accelerated detection or prevented the event.

DEA Requirements for Drug Diversion Programs

The Drug Enforcement Administration enforces the Controlled Substances Act, and hospitals that dispense controlled substances are DEA registrants with specific legal obligations.

Recordkeeping. DEA registrants must maintain complete and accurate records of all Schedule II controlled substance transactions and be able to produce them on demand. Perpetual inventory for Schedule II agents must reconcile against every receipt, dispense, and waste event.

Reporting theft and significant loss. Any theft or significant loss of controlled substances must be reported to the DEA on Form 106 within one business day of confirmation.

DEA inspections. DEA investigators may conduct inspections for a variety of reasons, including scheduled reviews, reports of loss or theft, patient complaints, or requests from the hospital. Inspectors will review controlled substance records, tour storage areas, and interview staff. The ability to produce accurate, well-organized records quickly is critical to a successful inspection.

Common compliance failures. Hospitals frequently fail to maintain adequate records for Schedule II agents, fail to report confirmed diversion within the required window, or fail to ensure that non-employee anesthesia staff comply with controlled substance handling requirements. The Medicare Conditions of Participation require compliance with applicable federal, state, and local laws, meaning that a DEA violation also puts Medicare participation at risk.

How to Build a Drug Diversion Prevention Program

For health systems building or strengthening a drug diversion program, the following framework reflects current best practices as defined by ASHP, The Joint Commission, and leading diversion prevention experts.

1. Establish Governance

Appoint a dedicated diversion compliance officer or establish a multidisciplinary governance committee. Define roles, reporting lines, and meeting cadence. Engage executive leadership to ensure program authority and budget.

2. Conduct a Risk Assessment

Map every setting where controlled substances are handled: central pharmacy, ADCs on nursing units, the OR and procedural suites, emergency department, satellite pharmacies, and any hospital-owned retail pharmacies. Identify current monitoring gaps, policy gaps, and technology gaps.

3. Implement Technology

Manual monitoring cannot scale to the transaction volume of a modern hospital. Implement a diversion monitoring platform that integrates with your ADC systems, EHR, wholesaler data, and controlled substance vault. Select a platform that automates reconciliation, provides behavioral analytics, and generates actionable risk scores rather than raw alert lists that overwhelm staff.

4. Define Policies and Procedures

Establish written policies for every step of the medication-use process. Ensure that waste documentation requirements, access controls, override policies, and discrepancy reporting procedures are clear, consistent, and enforced across all care settings.

5. Train All Relevant Staff

Education should reach every staff member who handles controlled substances: nurses, pharmacy staff, anesthesia providers, and anyone with ADC access. Training should cover the signs of diversion, how to report concerns, and the consequences of diversion, both for patients and for the diverting individual.

6. Monitor, Investigate, and Improve

Diversion monitoring is not a program you implement and leave unchanged. Review program metrics regularly: detection rates, time from diversion onset to detection, false positive rates, investigation closure rates. Benchmark against peer institutions. The Bluesight Diversion Collective provides a community of practice for diversion program leaders to share benchmarks and best practices.

Drug Diversion Monitoring Software: What to Look For

The market for drug diversion monitoring technology has consolidated significantly in recent years. In 2025, Bluesight’s ControlCheck holds approximately 40% market share with more than 2,000 hospital clients, and has been named Best in KLAS for Drug Diversion Monitoring five times.

When evaluating drug diversion monitoring software, the following criteria matter most.

Data source breadth. The platform should ingest data from ADCs, EHR/MAR, wholesaler, controlled substance vault, and HR systems at minimum. Programs that monitor only ADC data miss diversion that occurs in purchasing, stocking, and anesthesia.

Automated reconciliation. Manual reconciliation of controlled substance transactions is time-consuming and error-prone. Look for platforms that automate the reconciliation of individual dispenses against corresponding patient records, waste documentation, and returns – flagging only the exceptions that require human review.

Behavioral analytics. Transaction-level monitoring catches documentation errors. Behavioral analytics catch the patterns that precede documented diversion: who is wasting more than their peers, who is dispensing at unusual times, whose patient population should not require the volume of controlled substances being dispensed. IRIS from ControlCheck applies this lens across all monitored staff.

Workflow coverage. Verify that the platform covers all care settings relevant to your organization: nursing, OR/anesthesia, inpatient pharmacy, and retail pharmacy. Many platforms have strong nursing coverage but limited OR and retail pharmacy functionality.

False positive management. Alert fatigue is a real problem. Platforms that generate high false positive rates cause coordinators to stop trusting the system and reduce the rigor of their reviews. Look for evidence that the platform’s alert precision improves over time as it learns from your team’s feedback.

AI capabilities. Emerging AI capabilities – particularly natural language interfaces for investigation analysis, predictive risk scoring, and automated case summarization – are differentiating leading platforms from legacy tools. ControlCheck’s Prism Assistant is the only AI assistant in the market built specifically for controlled substance data.

Clinical support and partnership. Technology is a tool. The clinical support team behind it shapes outcomes. Diversion program leaders consistently cite the quality of vendor support as a critical success factor – particularly for investigation guidance, regulatory questions, and program benchmarking.

Frequently Asked Questions

What is drug diversion in healthcare?
Drug diversion is the unauthorized removal, theft, or misuse of prescription medications — particularly controlled substances — by healthcare workers or others with access to the medication supply. It encompasses personal use, resale, and substitution of medications with non-therapeutic substances.

How common is drug diversion in hospitals?
Drug diversion is estimated to occur at least 37,000 times per year in U.S. healthcare facilities, and the vast majority of incidents go undetected or unreported. Approximately 1 in 100 healthcare workers is actively diverting at any given time.

What are the most common drugs diverted in hospitals?
Opioids — particularly fentanyl, hydromorphone, and morphine — account for the majority of diversion. Benzodiazepines, anesthetic agents, and increasingly non-controlled substances including ondansetron, insulin, gabapentin, and Ozempic are also diverted.

How do hospitals detect drug diversion?
Modern hospitals use technology-based diversion monitoring platforms that aggregate transaction data from ADCs, EHRs, wholesaler systems, and pharmacy vaults and apply automated reconciliation and behavioral analytics to identify statistical anomalies. Without technology, detection relies on manual audits, complaints from patients or colleagues, and randomized drug testing — all of which detect only a fraction of actual diversion.

What is the Best-in-KLAS drug diversion monitoring software?
Bluesight’s ControlCheck has been named Best in KLAS for Drug Diversion Monitoring five years, most recently in 2025 with a customer satisfaction score of 86.1. KLAS Research is the independent healthcare IT analyst firm that surveys hospital customers to evaluate vendor performance.

What are ASHP guidelines on drug diversion?
ASHP published updated guidelines on preventing diversion of controlled substances in 2022. The guidelines recommend that health systems implement a multidisciplinary diversion governance structure, use technology for surveillance, establish policies covering the full medication-use process, train all relevant staff, and conduct regular program audits. ASHP also recommends extending monitoring to high-risk non-controlled substances.

Do hospitals have to report drug diversion to the DEA?
Yes. Confirmed theft or significant loss of controlled substances must be reported to the DEA on Form 106 within one business day of confirmation. Many hospitals fail to make this required report, which violates DEA regulations and the Medicare Conditions of Participation.

How does AI improve drug diversion detection?
AI and machine learning improve drug diversion detection by identifying behavioral patterns that precede confirmed diversion events, reducing false positive rates over time, and enabling coordinators to query large datasets in natural language rather than manually building reports. Platforms with AI capabilities consistently surface diversion earlier than those relying on static rule-based alerts.

What is closed-loop reconciliation for controlled substances?
Closed-loop reconciliation is the automated process of tracing each controlled substance dispense through its corresponding patient administration record, waste documentation, or return — verifying that the full amount dispensed is accounted for. ControlCheck automatically reconciles 95% of transactions, flagging only unresolved discrepancies for coordinator review.

How do you prevent drug diversion in a hospital pharmacy?
Preventing diversion in a hospital pharmacy requires controlled access to vaults and ADC stocking areas, witnessed counts for scheduled substances, automated reconciliation of all transactions, behavioral monitoring of pharmacy staff activity, and regular audits that are reviewed by someone not involved in the workflow being audited. Technology is essential at the transaction volumes involved in any large pharmacy.

What are the consequences of drug diversion for a hospital?
Consequences include direct harm to patients who receive substituted or diluted medications, exposure to bloodborne pathogens from shared syringes, DEA enforcement actions and fines, loss of Medicare and Medicaid participation, civil liability, reputational damage, and the human cost of staff members whose substance use disorder goes unaddressed and untreated.

Why ControlCheck Is the Standard for Drug Diversion Monitoring

Bluesight’s ControlCheck is the most widely used and most consistently top-rated drug diversion monitoring platform in the industry. Five Best-in-KLAS designations reflect what hospital diversion program leaders consistently report: that ControlCheck detects more, generates fewer false positives, and supports more effective investigations than alternatives.

The platform’s differentiated capabilities include:

• 95% automated transaction reconciliation. Your team reviews exceptions, not the entire transaction log. Time saved on reconciliation is time reinvested in investigations.
• IRIS behavioral risk scoring. Every monitored staff member receives a risk score based on their complete behavioral profile, compared to peers in similar roles and settings. The IRIS Worklist prioritizes the cases most likely to involve actual diversion, so coordinators investigate in the right order.
• Complete care setting coverage. Nursing, OR/anesthesia, inpatient pharmacy, and retail pharmacy are all monitored within a single platform. No blind spots.
• Prism Assistant. The industry’s only AI assistant built for controlled substance data. Ask questions in plain language and receive structured, evidence-backed answers in under 60 seconds. Investigation analysis that used to take hours takes minutes.
• Unlimited user seats. Nursing managers, pharmacy directors, anesthesia chiefs, compliance officers, and HR can all participate in diversion monitoring without adding per-seat cost. Cross-departmental visibility is how programs catch what pharmacy-only programs miss.
• Diversion Collective. A community where ControlCheck clients benchmark their program metrics against peers, share detection strategies, and learn from confirmed cases across the industry. No other vendor offers this level of structured peer learning for diversion program leaders.

If your organization is evaluating drug diversion monitoring software, is building a new diversion program, or is looking to extend monitoring to settings like the OR or retail pharmacy that your current solution does not cover, contact Bluesight to see how ControlCheck fits your environment.